Navigation Links
CompanDX Ltd. and Clinical Reference Laboratory, Inc. Sign Multi-Year Deal in Support of Collaborative Gene Signature and Companion Diagnostic Development

LENEXA, Kan., Feb. 19, 2011 /PRNewswire/ -- CompanDX Ltd., bioinformatics partner for the life sciences industry, and Clinical Reference Laboratory, Inc. (CRL), provider of laboratory testing services in molecular diagnostics and clinical trials, today announced they entered into a multi-year agreement to collaborate in the development and support of biomarker panels and companion diagnostic development for pharmaceutical, biotech and academic clients worldwide. Under the terms of the agreement, CompanDX will continue its trailblazing bioinformatics work on its "Distiller" platform, which includes the development of the first "Time to Event" breast cancer signature supported by CRL's CLIA-certified laboratory services.

The agreement today paves the way for CRL and CompanDX to deliver "discovery to validated test" services to their respective clients.  "CRL has a strong, long-standing reputation for providing state-of-the-art CLIA-certified testing services. In forging this relationship it allows us to reach both upstream and downstream to significantly broadening our reach into the growing market of Molecular Diagnostics, Stratified Clinical Trails and Personalized Medicine," said AD Sutton, CEO, CompanDX.

"Clients are looking for our help to support their clinical development programmes either by reducing the complexity of genomic or proteomic data or by proving innovative MDx tests that will allow them to stratify clinical trials.  CRL brings a level of expertise in the design and delivery of MDx tests that ideally compliments our innovative approach."

CRL's Executive Director of Molecular Diagnostics, Dr. Heather Fehling agrees, "CRL and CompanDX created a powerful team to help meet client's challenges in identifying meaningful biomarker panels and developing novel MDx testing for those panels.  CRL is excited to link its years of CLIA-certified laboratory experience with CompanDX's cutting edge bioinformatics tools to create a unique team offering quality molecular services."

CompanDX's bioinformatics technology will be exhibited at CRL's Booth #630 at the Molecular Medicine Tri-Conference in San Francisco from February 23-25, 2011. CompanDX will also present three posters at the main Tri-Conference, describing novel "Time to Event" breast cancer and "Effect Based" TB tests and an innovative systems biology tool "Therapy Distiller."  In addition, Adam Gouldsworthy, Ph.D., Business Development Manager, CompanDX is presenting a talk, ""Distilling" Personalized Medicine – From Biomarker Discovery to "Time-to-Event Prognostics" at the Early Oncology Partnering Forum in San Francisco on February 21 at 3.26 p.m.

About CompanDX Ltd.

CompanDX is a biomarker discovery and service company that uses its "Distiller" platform to derive small composite biomarker panels from clients genomic and proteomic data in support of stratified clinical trials.  Privately-held, CompanDX is based in Nottingham, UK. Investors in the company include Lachesis and Mobius Funds. Additional information is available at

About Clinical Reference Laboratory, Inc.

Established in 1979, CRL is a privately held reference laboratory in Lenexa, Kansas offering leading-edge testing services in the areas of Clinical Trials, Corporate Wellness Programs, Genomics, Insurance, Molecular Diagnostics, BioAnalytics and Toxicology. CRL is one of the largest single-site laboratories in the US and analyzes over 100 million tests annually.  In addition, CRL has a satellite laboratory near Cambridge, UK.  Additional information is available at

SOURCE Clinical Reference Laboratory, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
(Date:6/26/2016)... Story Highlights: ... the health care industry is causing providers to review ... Deloitte offers a suite of solutions for health care ... cost optimization: labor resource analysis, revenue cycle optimization and ... outcomes and better economics ...
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
(Date:6/24/2016)... , June 24, 2016 Research ... World Market for Companion Diagnostic Tests" report to their ... Market for Companion Diagnostics The World Market ... and personalized medicine diagnostics. Market analysis in the report includes ... Test Market (In Vitro Diagnostic Kits) by Region (N. America, ...
Breaking Medicine Technology:
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... ... 24, 2016 , ... Those who have experienced traumatic events may suffer from ... avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid this ... coping following a traumatic event. , Trauma sufferers tend to feel a range of ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
Breaking Medicine News(10 mins):